Quoin Pharmaceuticals Q1 EPS $(1.11) Compared With $(4.09) YoY, Quoin Had Approximately $14.7M In Cash & Equivalents As Of March 31, 2024
Portfolio Pulse from Benzinga Newsdesk
Quoin Pharmaceuticals (QNRX) reported a Q1 EPS loss of $(1.11), missing the consensus estimate of $(0.76) by 46.05%. Despite this, the loss represents a 72.79% improvement from last year's $(4.08) per share. As of March 31, 2024, Quoin had $14.7M in cash and equivalents.
May 09, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Quoin Pharmaceuticals reported a Q1 EPS loss of $(1.11), missing estimates but showing significant year-over-year improvement. Cash position is $14.7M.
Missing the EPS estimate by 46.05% is likely to negatively impact investor sentiment in the short term, despite the year-over-year improvement in losses. The cash position provides some stability, but the missed expectations could lead to a decrease in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100